Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.
Lee
Edwin
E
Leung
Chi-Ming
CM
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000009:adverse effects*; D002681:China; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D050171:Dyslipidemias / Q000139:chemically induced* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000378:metabolism; D000077152:Olanzapine; D010865:Pilot Projects; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D012737:Sex Factors; D055815:Young Adult
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine